Pharma 5.0

AI in pharma: Practical use cases transforming research, regulatory and medical affairs

AI and digital transformation expert Sarah Chan explores the rapidly expanding role of artificial intelligence across the pharmaceutical value chain

Drawing from her experience leading global AI initiatives at MSD and her work with TOPRA, Sarah presents a practical and detailed walkthrough of how AI is already reshaping R&D, regulatory affairs, clinical operations, and medical information — and what is required for safe, ethical, and effective adoption.

Sarah explains why AI is no longer optional for organisations facing rising R&D costs, longer development cycles, fragmented regulatory requirements, and rapidly growing volumes of multimodal data. She then shares real-world use cases, including:

  • AI in early research: accelerating target identification, protein interaction analysis, and compound screening.
  • AI in clinical development: assisting with protocol drafting, patient selection criteria, endpoint identification, study team chatbots, patient-facing support tools, and producing first-draft clinical study reports in days rather than months.
  • AI in regulatory affairs: large-scale translation, mining regulatory questions to identify trends, generating first-draft responses, and supporting global submission planning by analysing complex strategic factors.
  • AI in medical affairs: literature summarisation, insight generation from HCP interactions, congress intelligence scanning, and drafting medical information documents.
  • Data readiness challenges: why metadata accuracy, validation, and system interoperability are essential prerequisites for any successful AI program.

She also outlines the current and emerging regulatory landscape, emphasising the need for a risk-based approach, strong governance, human oversight, clear documentation, and output explainability. These safeguards ensure AI enhances product quality, regulatory compliance, and patient safety.

Her core message is clear: AI is not just an operational tool — it is a strategic enabler. To harness its full value, pharma organisations must invest in technology, people, training, cross-functional collaboration, and responsible frameworks for implementation.

This presentation provides actionable insights and real examples that teams can begin applying immediately.

Relevant companies

You may also like